Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Top 200 Medicines Annual Report 2019: The king of medicines

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

Read More »

Novartis teams with interior designer to help wet AMD patients

Novartis has teamed up with celebrity interior designer Nate Berkus to launch My Home in Sight, a program that aims to raise awareness of the daily impact of wet age-related macular degeneration and empower those living with wet AMD and their caregivers to make simple, functional changes to support safety and independence at home.

Read More »

Kala Pharmaceuticals Receives FDA CRL for KPI-121 0.25% NDA

Kala Pharmaceuticals Inc. received a complete response letter from the U.S. Food and Drug Administration regarding the company’s new drug application for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

Read More »

Glaukos and Avedro Announce Definitive Acquisition Agreement

Ophthalmic medical technology and pharmaceutical company Glaukos Corp. will acquire hybrid ophthalmic pharma and medical tech company Avedro Inc. in an all-stock transaction.

Read More »

Allergan beats profit; raises 2019 revenue forecast on Restasis, Juvederm demand

Allergan Plc – which is being bought by AbbVie Inc. for $63 billion – beat second-quarter 2019 profit estimates and raised the company’s full-year revenue forecast, helped by demand for the dry eye drug Restasis and aesthetics product Juvederm.

Read More »

FDA Approves Otezla for Treatment of Oral Ulcers Associated with Behçet’s Disease

The U.S. Food and Drug Administration approved Celgene Corp.’s Otezla (apremilast) 30 mg twice daily for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Read More »

FDA Approves Eylea for Diabetic Retinopathy

The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.

Read More »

Novartis buys dry-eye drug from Takeda for up to $5.3 billion

Novartis is buying the projected blockbuster dry-eye drug Xiidra from Takeda Pharmaceutical for up to $5.3 billion.

Read More »

Future of Healthcare

I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.

Read More »

Novartis Announces FDA Filing Scceptance, Priority Review Of Brolucizumab For Patients With Wet AMD

Novartis announced that the U.S. Food and Drug Administration accepted the company’s Biologics License Application for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom